Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 1/2016

01-06-2016 | Case Report

A Rare Case of Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplant Patient

Authors: Kamal Kant Sahu, Gaurav Prakash, Alka Khadwal, Subhash Chander Varma, Pankaj Malhotra

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2016

Login to get access

Abstract

Post bone marrow transplant patients are susceptible to atypical infections, especially viral pathogens. The risk increases many folds in cases of allogeneic transplantation, which also receive GVHD prophylaxis. Viral pathogens like cytomegalovirus and herpes are the common ones encountered during follow-up period. However, in recent times there have been reports of a variety of disease manifestations of rare viruses like polyoma virus and adenovirus. These viral infections may play a crucial role in morbidity and mortality in immunocompromised patients. We hereby elaborate the follow-up course of a 36-year-old post allogeneic transplant patient of acute myeloid leukemia who developed adenovirus related haemorrhagic cystitis. Treatment with oral ribavirin lead to dramatic improvement in symptomatology within a week. This cases re-emphasizes the fact that after ruling out the commoner pathogens, it’s of utmost importance to strongly consider the atypical pathogens in such cases.
Literature
1.
Brugieres L, Hartmann O, Travagli JP, Benhamou E, Pico JL, Valteau D et al (1989) Hemorrhagic cystitis following high-dose chemotherapy and bone marrow transplantation in children with malignancies: incidence, clinical course, and outcome. J Clin Oncol 7(2):194–199PubMed
2.
Seber A, Shu XO, Defor T, Sencer S, Ramsay N (1999) Risk factors for severe hemorrhagic cystitis following BMT. Bone Marrow Transplant 23(1):35–40CrossRefPubMed
3.
La Rosa AM, Champlin RE, Mirza N, Gajewski J, Giralt S, Rolston KV et al (2001) Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 32(6):871–876CrossRefPubMed
4.
Hale GA, Heslop HE, Krance RA, Brenner MA, Jayawardene D, Srivastava DK et al (1999) Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant 23(3):277–282CrossRefPubMed
5.
Suparno C, Milligan DW, Moss PA, Mautner V (2004) Adenovirus infections in stem cell transplant recipients: recent developments in understanding of pathogenesis, diagnosis and management. Leuk Lymphoma 45(5):873–885CrossRefPubMed
6.
Runde V, Ross S, Trenschel R, Lagemann E, Basu O, Renzing-Kohler K et al (2001) Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. Bone Marrow Transplant 28(1):51–57CrossRefPubMed
7.
Flomenberg P, Babbitt J, Drobyski WR, Ash RC, Carrigan DR, Sedmak GV et al (1994) Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 169(4):775–781CrossRefPubMed
8.
Akiyama H, Kurosu T, Sakashita C, Inoue T, Mori S, Ohashi K et al (2001) Adenovirus is a key pathogen in hemorrhagic cystitis associated with bone marrow transplantation. Clin Infect Dis 32(9):1325–1330CrossRefPubMed
9.
Childs R, Sanchez C, Engler H, Preuss J, Rosenfeld S, Dunbar C et al (1998) High incidence of adeno- and polyomavirus-induced hemorrhagic cystitis in bone marrow allotransplantation for hematological malignancy following T cell depletion and cyclosporine. Bone Marrow Transplant 22(9):889–893CrossRefPubMed
10.
Thomas AE, Patterson J, Prentice HG, Brenner MK, Ganczakowski M, Hancock JF et al (1987) Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy. Bone Marrow Transplant 1(4):347–355PubMed
11.
Mori Y, Miyamoto T, Kato K, Kamezaki K, Kuriyama T, Oku S et al (2012) Different risk factors related to adenovirus- or BK virus-associated hemorrhagic cystitis following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 18(3):458–465CrossRefPubMed
12.
Kawakami M, Ueda S, Maeda T, Karasuno T, Teshima H, Hiraoka A et al (1997) Vidarabine therapy for virus-associated cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 20(6):485–490CrossRefPubMed
13.
14.
Fanourgiakis P, Georgala A, Vekemans M, Triffet A, De Bruyn JM, Duchateau V et al (2005) Intravesical instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient. Clin Infect Dis 40(1):199–201CrossRefPubMed
15.
Morfin F, Dupuis-Girod S, Mundweiler S, Falcon D, Carrington D, Sedlacek P et al (2005) In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther 10(2):225–229PubMed
16.
Gavin PJ, Katz BZ (2002) Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics 110(1 Pt 1):e9CrossRefPubMed
17.
Miyamura K, Hamaguchi M, Taji H, Kanie T, Kohno A, Tanimoto M et al (2000) Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors. Bone Marrow Transplant 25(5):545–548CrossRefPubMed
18.
Cassano WF (1991) Intravenous ribavirin therapy for adenovirus cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 7(3):247–248PubMed
19.
Lakhani A, Raptis A, Frame D, Simpson D, Berkahn L, Mellon-Reppen S et al (1999) Intravesicular instillation of E-aminocaproic acid for patients with adenovirus-induced hemorrhagic cystitis. Bone Marrow Transplant 24(11):1259–1260CrossRefPubMed
20.
Laszlo D, Bosi A, Guidi S, Saccardi R, Vannucchi AM, Lombardini L et al (1995) Prostaglandin E2 bladder instillation for the treatment of hemorrhagic cystitis after allogeneic bone marrow transplantation. Haematologica 80(5):421–425PubMed
21.
Metadata
Title
A Rare Case of Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplant Patient
Authors
Kamal Kant Sahu
Gaurav Prakash
Alka Khadwal
Subhash Chander Varma
Pankaj Malhotra
Publication date
01-06-2016
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0530-5

Other articles of this Special Issue 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Go to the issue

Correspondence

Obstructive Uropathy as an Initial Presentation of Primary Myelofibrosis: Case Report and Review of Literature

Short Communication

Dasatinib and Dysfunction of Platelets

Correspondence

A Novel A1088T Mutation in the Glucose-6-Phosphate Dehydrogenase Gene Detected by RT-PCR Combined with DNA Sequencing

Case Report

Therapy Related Acute Myeloid Leukemia with t(8;16) Mimicking Acute Promyelocytic Leukemia

Case Report

Effective Treatment of a Childhood Blastic Plasmacytoid Dendritic Cell Neoplasm with a Cutaneous Tumor Alone by Stem Cell Transplantation with Reduced Intensity Conditioning

Case Report

Plasmablastic Lymphoma of Small Intestine: A Rare Case Report with Review of Literature
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits